tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2024 Nov 25;11(12)
fae689.
doi: 10.1093/ofid/ofae689. eCollection 2024 Dec. Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann[SUP] 1 [/SUP], Xiaowei Wang[SUP] 2 [/SUP], Lindsey R Baden[SUP] 3 [/SUP], Hana M El Sahly[SUP] 4 [/SUP], Brandon Essink[SUP] 5 [/SUP], Peter Gilbert[SUP] 6 [/SUP], Holly E Janes[SUP] 6 [/SUP], Colleen F Kelley[SUP] 7 [/SUP], Megan A Berman[SUP] 8 [/SUP], Ian Frank[SUP] 9 [/SUP], Eric Chu[SUP] 1 [/SUP], Weiping Deng[SUP] 2 [/SUP], Frances Priddy[SUP] 2 [/SUP], Avika Dixit[SUP] 2 [/SUP], Joanne E Tomassini[SUP] 2 [/SUP], Rituparna Das[SUP] 2 [/SUP], Jacqueline Miller[SUP] 2 [/SUP], Honghong Zhou[SUP] 2 [/SUP]
Affiliations
Background: To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273.
Methods: Approximately 17 000 participants from the phase 3 Coronavirus Efficacy trial who previously received 2 doses of 100 µg mRNA-1273 were evaluated for COVID-19 between September 2021 and April 2022 during uptake of a third booster dose of 50 µg of mRNA-1273. Cox models assessed booster relative efficacy of a third dose.
Results: Initial booster relative efficacy against Delta COVID-19 was 83% (95% confidence interval, 60-93) 14 days postdose and 83% (67-91) 60 days later. Initial booster efficacy against Omicron COVID-19 was 56% (44-65) at 14 days postdose and 4% (-27 to 28) 120 days later. For those aged ≥65 years, initial booster efficacy against Omicron COVID-19 was 86% (69-93) compared with 50% (36-61) for those <65 years. Placebo crossover to 2 doses of mRNA-1273 induced a median 5-month difference from the second to third dose between the original randomized arms. Postboost, the mRNA-1273 arm had a 24% (16%, 32%) lower risk of Omicron COVID-19 compared to the placebo-mRNA-1273 arm. Modeling predicted a 41% postboost reduction in Omicron COVID-19 for a 15- versus 7-month interval between the second and third doses.
Conclusions: Boosting reduced Delta COVID-19 risk by 83% through 2 months and reduced Omicron COVID-19 risk by 56% but declined by 4 months. A 15- versus 7-month dosing interval predicted a 41% postboost reduction in Omicron COVID-19 but increased preboost risk.
Primary funding source: The National Institutes of Health/National Institute of Allergy and Infectious Diseases. Registration for the COVE Trial. ClinicalTrials.gov ID# NCT04470427.
Keywords: COVID-19 vaccine; SARS-CoV2; booster dose; mRNA-1273.
. 2024 Nov 25;11(12)
fae689.doi: 10.1093/ofid/ofae689. eCollection 2024 Dec. Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial
Dean Follmann[SUP] 1 [/SUP], Xiaowei Wang[SUP] 2 [/SUP], Lindsey R Baden[SUP] 3 [/SUP], Hana M El Sahly[SUP] 4 [/SUP], Brandon Essink[SUP] 5 [/SUP], Peter Gilbert[SUP] 6 [/SUP], Holly E Janes[SUP] 6 [/SUP], Colleen F Kelley[SUP] 7 [/SUP], Megan A Berman[SUP] 8 [/SUP], Ian Frank[SUP] 9 [/SUP], Eric Chu[SUP] 1 [/SUP], Weiping Deng[SUP] 2 [/SUP], Frances Priddy[SUP] 2 [/SUP], Avika Dixit[SUP] 2 [/SUP], Joanne E Tomassini[SUP] 2 [/SUP], Rituparna Das[SUP] 2 [/SUP], Jacqueline Miller[SUP] 2 [/SUP], Honghong Zhou[SUP] 2 [/SUP]
Affiliations
- PMID: 39679349
- PMCID: PMC11639572
- DOI: 10.1093/ofid/ofae689
Background: To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273.
Methods: Approximately 17 000 participants from the phase 3 Coronavirus Efficacy trial who previously received 2 doses of 100 µg mRNA-1273 were evaluated for COVID-19 between September 2021 and April 2022 during uptake of a third booster dose of 50 µg of mRNA-1273. Cox models assessed booster relative efficacy of a third dose.
Results: Initial booster relative efficacy against Delta COVID-19 was 83% (95% confidence interval, 60-93) 14 days postdose and 83% (67-91) 60 days later. Initial booster efficacy against Omicron COVID-19 was 56% (44-65) at 14 days postdose and 4% (-27 to 28) 120 days later. For those aged ≥65 years, initial booster efficacy against Omicron COVID-19 was 86% (69-93) compared with 50% (36-61) for those <65 years. Placebo crossover to 2 doses of mRNA-1273 induced a median 5-month difference from the second to third dose between the original randomized arms. Postboost, the mRNA-1273 arm had a 24% (16%, 32%) lower risk of Omicron COVID-19 compared to the placebo-mRNA-1273 arm. Modeling predicted a 41% postboost reduction in Omicron COVID-19 for a 15- versus 7-month interval between the second and third doses.
Conclusions: Boosting reduced Delta COVID-19 risk by 83% through 2 months and reduced Omicron COVID-19 risk by 56% but declined by 4 months. A 15- versus 7-month dosing interval predicted a 41% postboost reduction in Omicron COVID-19 but increased preboost risk.
Primary funding source: The National Institutes of Health/National Institute of Allergy and Infectious Diseases. Registration for the COVE Trial. ClinicalTrials.gov ID# NCT04470427.
Keywords: COVID-19 vaccine; SARS-CoV2; booster dose; mRNA-1273.